Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05549154
Other study ID # XJTU1AF2022LSK-320
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 5, 2022
Est. completion date October 30, 2023

Study information

Verified date January 2023
Source First Affiliated Hospital Xi'an Jiaotong University
Contact Hongli Jiang, Professor
Phone 13700280897
Email j92106@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. Study content: This is a multicentre, double-blind, randomised controlled study to determine the optimal dose and duration of treatment for the correction of vitamin D insufficiency or deficiency in patients with CKD5d; to investigate whether vitamin D supplementation delays the increase in PTH levels in this group of patients; and to investigate the effects on changes in CKD-MBD-related markers, cardiovascular complications, cognitive function in this group of patients. 2. Study procedure: Based on the inclusion and exclusion of the patients, the study was conducted in accordance with the following criteria 2. Study procedure: Eligible subjects were screened according to inclusion and exclusion criteria and randomly divided into three groups: high-dose vitamin D group, low-dose vitamin D group and control group. Baseline data were collected before the intervention and each group was given different doses of regular vitamin D2 softgels or placebo and followed up. 25(OH)D, PTH, blood Ca, and blood P levels were measured every month; bone metabolism markers, FGF23, and blood counts, liver function, kidney function, lipids, and blood glucose were measured every 3 months; the prevalence of vascular calcification, the incidence of cardiovascular events, and changes in cognitive function scale scores were assessed 6 months after the intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 372
Est. completion date October 30, 2023
Est. primary completion date August 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Age = 18 years. 2. Patients with chronic kidney disease stage 5d who have been on haemodialysis for 3 months or more 3. 5 ng/mL < 25(OH)D < 30 ng/mL (liquid phase tandem mass spectrometry). 4. 130 pg/ml < PTH < 600 pg/ml (electrochemiluminescence method). 5. serum phosphorus < 1.78 mmol/L. 6. Good compliance with the treatment requirements formulated for the study. 7. informed consent from the subject. Exclusion Criteria: 1. Patients who are prepped for or have undergone renal transplantation or parathyroidectomy. 2. taking vitamin D, active vitamin D or analogues and other drugs that may affect 25(OH)D levels within 3 months prior to enrolment 3. Treatment affecting PTH results (e.g. cenacaser, etc.) within 3 months prior to enrolment 4. Serum calcium > 2.55 mmol/L 5. Patients who are pregnant or likely to become pregnant, breastfeeding or planning to become pregnant during the study period 6. known prior or concomitant serious illness or medical condition such as malignancy, human immunodeficiency virus, severe gastrointestinal or liver disease, intestinal malabsorptive disease, hepatitis or cardiovascular events that may worsen or shorten life expectancy and/or interfere with participation in the study 7. History of neurological/psychiatric disease, including psychosis or dementia, or any other reason that is unlikely to result in adherence to treatment or follow-up plans. 8. Known or suspected allergy to any component of the study drug. 9. Ongoing participation in other clinical studies.

Study Design


Intervention

Drug:
High-dose vitamin D2 softgels
5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D > 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
low-dose vitamin D2 softgels
5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D > 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
placebo
placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).

Locations

Country Name City State
China The First Affiliated Hospital of Xi 'an Jiaotong University Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in changes in PTH levels from baseline to 6 months of intervention baseline,at 6 months intervention
Secondary Differences in changes in PTH levels from baseline to intervention at 1months?2months?3months?4months?5months baseline,at 1,2,3,4,5 months intervention
Secondary Proportion of 25(OH)D >30ng/ml at 3 months of intervention at 3 months intervention
Secondary Trends in changes in 25(OH)D levels from baseline to intervention at 1months?2months?3months?4months?5months?6months baseline,at 1,2,3,4,5,6 months intervention
Secondary Incidence of cardiovascular events after 6 months of intervention baseline,at 6 months intervention
Secondary Change in prevalence of vascular calcification at 6 months of intervention We used cardiac ultrasound and lateral abdominal views to look for vascular calcification baseline,at 6 months intervention
Secondary Change in Montreal Cognitive Assessment Scale scores at 6 months of intervention A total score of 30 on this scale, with a score of =26 indicating normal; a score of <26 indicates the presence of cognitive impairment: 18-26 for mild cognitive impairment, 10-17 for moderate cognitive impairment and <10 for severe cognitive impairment baseline,at 6 months intervention
Secondary Trends in blood calcium levels at 1 month, 2 months, 3 months, 4 months, 5 months and 6 months of intervention baseline,at 1,2,3,4,5,6 months intervention
Secondary Trends in blood phosphorus levels at 1 month, 2 months, 3 months, 4 months, 5 months and 6 months of intervention baseline,at 1,2,3,4,5,6 months intervention
Secondary Trends in FGF23 levels at 3 and 6 months of intervention baseline,at 3,6 months intervention
Secondary Trends in Osteocalcin(OC) levels at 3 and 6 months of intervention baseline,at 3,6 months intervention
Secondary Trends in Precollagen type I amino-terminal peptide(PINP) levels at 3 and 6 months of intervention baseline,at 3,6 months intervention
Secondary Trends in ß specific collagen degradation products(ß-CTX) levels at 3 and 6 months of intervention baseline,at 3,6 months intervention
Secondary Trends in ALP levels at 3 and 6 months of intervention baseline,at 3,6 months intervention
Secondary Incidence of fractures at 6 months of intervention Ask if the patient had a fracture during the intervention, the site of the fracture and the type of fracture baseline,at 6 months intervention
Secondary Incidence of falls at 6 months of intervention Ask if the patient has fallen during the intervention, the number of falls and the reasons for them baseline,at 6 months intervention
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Recruiting NCT05459298 - ViDES Trial (Vitamin D Extra Supplementation) N/A
Completed NCT04476511 - The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules Phase 3
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03920150 - Vitamin D 24'000 IU for Oral Intermittent Supplementation Phase 3
Completed NCT03264625 - The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis Phase 2
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT05506696 - Vitamin D Supplementation Study N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Completed NCT03234218 - Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT02714361 - A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women N/A
Completed NCT02906319 - Vitamin D and HbA1c Levels in Diabetic Patients With CKD N/A
Completed NCT02118129 - Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'. N/A
Not yet recruiting NCT01419821 - Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5 N/A
Completed NCT02187146 - The Effects of Serum Vitamin D and IVF Outcome N/A
Completed NCT02275650 - The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter N/A
Completed NCT01688102 - The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile N/A
Completed NCT01651000 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3